Status:
COMPLETED
A Methodology Study Of Brain Imaging Of Pain-Killers In Post-Traumatic Neuropathic Pain Patients
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborating Sponsors:
University of Oxford
Conditions:
Pain
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This study is a methodology study designed to discover whether a brain imaging technology is a better way of compare the relative sensitivities of fMRI and subjective psychometric assessments of pain ...
Eligibility Criteria
Inclusion
- Diagnosis of neuropathic pain associated with brush allodynia in specific dermatomes.
- Brush allodynia score of ≥4 and calculated average pain score of ≥3 on an 11-point numerical rating scale by the completion of down-titration of existing medications.
- Right-handed
Exclusion
- Subjects with trigeminal neuralgia, central pain (due to cerebrovascular lesions, multiple sclerosis and/or traumatic spinal cord injuries including spinal surgery).
- Phantom limb pain, painful diabetic neuropathy.
- Subjects with any other co-existing pain which he/she or a qualified pain physician cannot differentiate from NeP of peripheral origin.
- Subjects with diabetes mellitus and with an HbA1C value of \>10% upon measurement at screening.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00610155
Start Date
September 1 2008
End Date
July 1 2010
Last Update
January 22 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Portsmouth, Hampshire, United Kingdom, PO3 6AD
2
Pfizer Investigational Site
Solihull, West Midlands, United Kingdom, B91 2JL